Skip to main content
Clinical Trials/NCT05217966
NCT05217966
Recruiting
Not Applicable

Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS) for Low Risk Breast Cancer: A Phase II Study

Maisonneuve-Rosemont Hospital2 sites in 1 country80 target enrollmentOctober 8, 2021
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Maisonneuve-Rosemont Hospital
Enrollment
80
Locations
2
Primary Endpoint
Incidence of pathological complete response
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Eligible women will receive neoadjuvant single fraction radiotherapy followed by surgery performed after one year

Registry
clinicaltrials.gov
Start Date
October 8, 2021
End Date
December 31, 2030
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michael Yassa

Radiation Oncologist

Maisonneuve-Rosemont Hospital

Eligibility Criteria

Inclusion Criteria

  • Female aged 50 years or older.
  • Postmenopausal status (Defined as: age 60 OR bilateral ovariectomy OR amenorrhea \> 12 months prior to breast cancer diagnosis without using oral contraceptives/hormone replacement therapy) (65).
  • World Health Organization (WHO) performance status 0-
  • Invasive ductal carcinoma proven by biopsy done ≤ 12 weeks from treatment start.
  • Unifocal disease on preoperative staging ultrasound or MRI done ≤ 12 weeks from treatment start.
  • Tumors less than or equal to 2cm clinically on physical exam, as well as on breast ultrasound.
  • No clinical evidence of nodal disease (i.e. cN0), on physical examination done ≤ 12 weeks from treatment start, as well as on breast ultrasound.
  • Estrogen receptor status (ER) positive on biopsy ≥ 80%.
  • Progesterone receptor status (PR) positive on biopsy ≥ 20%.
  • Her2 negative on biopsy.

Exclusion Criteria

  • Age less than 50 years.
  • Premenopausal or uncertain menopausal status.
  • A known deleterious mutation in BRCA 1 and/or BRCA
  • Clinical tumor size \> 2.0 cm in greatest diameter on staging ultrasound.
  • Tumor histology limited to lobular carcinoma only.
  • Clinically positive axillary nodes (cN+).
  • Lymphovascular invasion on biopsy.
  • Pure ductal or lobular carcinoma in situ on biopsy.
  • Extensive intraductal component on biopsy.
  • Neoadjuvant hormonal manipulation or chemotherapy.

Outcomes

Primary Outcomes

Incidence of pathological complete response

Time Frame: 12 months

Secondary Outcomes

  • Incidence of grade 3 or greater radiation toxicity(0-5 years)

Study Sites (2)

Loading locations...

Similar Trials